Company profile
TIZIANA LIFE SCIENCES LTD
NASDAQ:TLSABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FORALUMAB | phase2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06868628 | phase2 | recruiting | 2025-05-19 | 2027-04-01 | Tiziana Life Sciences LTD | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) |
| NCT06292923 | phase2 | active_not_recruiting | 2023-11-15 | 2026-09-01 | Tiziana Life Sciences LTD | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients |
| NCT05028946 | phase1 | withdrawn | 2022-05-01 | 2023-07-07 | Tiziana Life Sciences LTD | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease |
| NCT03291249 | phase2 | withdrawn | 2017-12-01 | 2018-12-01 | Tiziana Life Sciences LTD | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM |
| NCT04983446 | phase2 | withdrawn | 2022-04-30 | 2022-10-30 | Tiziana Life Sciences LTD | In-patient COVID-19 Study of Intranasal Foralumab |
FDA applications (0)
No records yet.